Open to recruitment in the United Kingdom
- Odronextamab (Bispecific antibody), Regeneron Pharmaceuticals Inc.
- Loncastuximab tesirine (Antibody Drug Conjugate) with standard chemotherapy, ADC Therapeutics SA
Under development
- Golcadomide (CELMoD™ agent) with Rituximab, Bristol Myers Squibb